LICENSING

ActoGeniX Enters Research Collaboration with Merck

Ghent, Belgium, November 12, 2012 -- ActoGeniX, a clinical stage biopharmaceutical company, today announces the signing of a research collaboration agreement with Merck, known as MSD outside of the United States and Canada, to develop and validate a therapeutic approach to an undisclosed indication using ActoBiotics^TM, a novel class of orally administered and locally acting biopharmaceuticals.

This approach is based on the oral administration and local enteric delivery of antibodies, which are expressed and secreted at the enteric mucosa by the ActoBioticsTM technology.

ActoBiotics^TM represent a novel concept for oral administration of therapeutic proteins. ActoBiotics^TM can deliver a wide range of therapeutic peptides and proteins, including monoclonal antibodies, antibody fragments, cytokines, antigens, and hormones.

About ActoGeniX

ActoGeniX is a biopharmaceutical company focused on the development and commercialization of ActoBiotics^TM, a novel class of orally available biopharmaceuticals for the targeted treatment of severe diseases with a high medical need. ActoBiotics^TM represent a novel concept for oral administration of therapeutic proteins, and are designed to be safer and more effective than injectable biopharmaceuticals. ActoBiotics^TM can deliver a wide range of therapeutic peptides and proteins, including cytokines, enzymes, hormones and monoclonal antibodies.

AG013, ActoGeniX´s lead product for the treatment of oral mucositis in cancer patients has been evaluated in a phase 1B clinical trial in the US, confirming safety and tolerability as well as initial efficacy. Moreover, in preclinical models, ActoGeniX has confirmed the broad applicability of ActoBiotics^TM and its proprietary technology platform for a wide range of diseases, including gastrointestinal, metabolic, immune diseases and allergies.

ActoGeniX was founded in 2006 as a spin-off from VIB and Ghent University. The Company is headquartered in Ghent (Belgium) and employs approximately 20 employees, half of whom are PhD's, MD's, or PharmD's. ActoGeniX raised 35.5 million Euro (approximately 50 million US$) in two equity financing rounds from a consortium of leading life sciences investors such as Gimv, Biotech Fund Flanders, Baekeland Fund, Biovest (Belgium), Life Sciences Partners, Aescap Venture (The Netherlands) and Ventech (France).

ActoGeniX has a strong and broad intellectual property position with a patent estate encompassing more than 20 distinct patent families. With broad patent claims already granted in major territories like the US and Europe, ActoGeniX is uniquely positioned to successfully exploit the commercial potential of its promising ActoBiotics^TM.

www.actogenix.com

<< Previous Press Release | Next Press Release >>

• Print
• Share
• Text Size
• Access